Australia's most trusted
source of pharma news
Thursday, 07 November 2024
Posted 4 November 2024 AM
Eight companies have scraped through and secured PBS listings for their drugs in the second-last round of announcements for 2025 - half the number of reimbursements delivered in October.
Newcomers include AstraZeneca's latest diabetes treatment Sidapvia, which was recommended by the PBAC in March ahead of the TGA's approval in June.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.